Earnings History Data for Fortress Biotech, Inc. (FBIO) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Fortress Biotech, Inc.

Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
14-08-2023	AH		FBIO	Fortress Biotech	71.00	-0.24	-0.26	0.00	Fortress Biotech Non-GAAP EPS of -$0.07 misses by $0.13, revenue of $17.39M misses by $6.6M [8/14/2023 5:02 PM]	0.5051	-0.03 (-6.12%)	0.48	-0.06 (-10.76%)	0.47 - 1.29	1,230,852	390,000	18,586
Fortress Biotech Non-GAAP EPS of -$0.07 misses by $0.13, revenue of $17.39M misses by $6.6M [8/14/2023 5:02 PM]
15-05-2023	AH		FBIO	Fortress Biotech	94.00	-0.21	-0.19	0.00	Fortress Biotech Non-GAAP EPS of -$0.06, revenue of $12.43M [5/15/2023 4:54 PM]	0.6551	-0.05 (-7.34%)	0.73	0.02 (3.10%)	0.48 - 1.33	692,598	410,000	16,410
Fortress Biotech Non-GAAP EPS of -$0.06, revenue of $12.43M [5/15/2023 4:54 PM]
30-03-2023	PM	4:00 PM ET (Mar 30)	FBIO	Fortress Biotech	84.00	-0.30	-0.22	0.00	Fortress Biotech Non-GAAP EPS of -$0.33 misses by $0.18, revenue of $75.7M misses by $23.67M [3/31/2023 12:31 AM]	0.8218	0.08 (10.46%)	0.80	0.06 (7.59%)	0.48 - 1.52	779,290	320,000	41,912
Fortress Biotech Non-GAAP EPS of -$0.33 misses by $0.18, revenue of $75.7M misses by $23.67M [3/31/2023 12:31 AM]
14-11-2022	PM		FBIO	Fortress Biotech	81.00	-0.25	-0.27	0.00	Fortress Biotech Non-GAAP EPS of -$0.08 misses by $0.01, revenue of $16.5M misses by $5.13M [11/15/2022 4:13 AM]	0.88	0.02 (2.68%)	0.88	0.02 (2.25%)	0.67 - 3.51	122,400	130,000	2,052
Fortress Biotech Non-GAAP EPS of -$0.08 misses by $0.01, revenue of $16.5M misses by $5.13M [11/15/2022 4:13 AM] Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates [Nov-14-22 05:25PM] Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights [Nov-14-22 04:05PM] Fortress Biotech Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights [Nov-14-22 04:01PM] Twist Bioscience (TWST) Surges 16.1%: Is This an Indication of Further Gains? [Nov-14-22 08:12AM]
11-08-2022	AH	4:00 PM ET (Aug 11)	FBIO	Fortress Biotech	119.00	-0.24	-0.20	0.00	Fortress Biotech Non-GAAP EPS of -$0.10 misses by $0.03, revenue of $18.89M misses by $4.29M [8/11/2022 4:59 PM]	1.26	-0.03 (-2.33%)	1.29	0.0 (0.00%)	0.77 - 3.81	325,509	390,000	607
Fortress Biotech Non-GAAP EPS of -$0.10 misses by $0.03, revenue of $18.89M misses by $4.29M [8/11/2022 4:59 PM] Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients [8/11/2022 9:26 AM] Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights [Aug-11-22 04:30PM] Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights [Aug-11-22 04:05PM] Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation [Aug-11-22 08:00AM]
12-05-2022	AH	After the close (May 12)	FBIO	Fortress Biotech	99.00	-0.18	-0.28	0.00	Fortress Biotech Non-GAAP EPS of -$0.07 misses by $0.08, revenue of $23.93M beats by $3.26M [5/12/2022 4:47 PM]	0.8511	0.05 (6.39%)	0.84	0.04 (5.01%)	0.79 - 4.49	472,060	670,000	8,922
Fortress Biotech Non-GAAP EPS of -$0.07 misses by $0.08, revenue of $23.93M beats by $3.26M [5/12/2022 4:47 PM] Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights [May-12-22 04:30PM] Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights [May-12-22 04:05PM] Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights [May-12-22 04:01PM] Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress [May-12-22 10:38AM] Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates [May-12-22 05:35PM] Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency [May-13-22 08:30AM]
28-03-2022	PM	Before the open (Mar 28)	FBIO	Fortress Biotech	139.00	-0.38	0.10	0.00	Fortress Biotech Non-GAAP EPS of $0.25 beats by $1.27, revenue of $68.79M misses by $26.25M [3/28/2022 9:06 AM]	1.42	0.08 (5.97%)	1.42	0.0 (0.00%)	1.23 - 6.10	835,837	410,000	1,046
Fortress Biotech Non-GAAP EPS of $0.25 beats by $1.27, revenue of $68.79M misses by $26.25M [3/28/2022 9:06 AM] Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights [Mar-28-22 08:00AM] Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights [Mar-28-22 07:30AM]
16-05-2021	PM		FBIO	Fortress Biotech, Inc.	351.09	-0.11	-0.17	-0.07	Fortress Biotech EPS misses by $0.04, misses on revenue [5/17/2021 12:02 AM]	3.55	-0.13 (-3.53%)	3.69	0.01 (0.27%)	2.12 - 6.10	777,776	960,000	2,807
Fortress Biotech EPS misses by $0.04, misses on revenue [5/17/2021 12:02 AM] Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights [May-14-21 04:30PM] REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights [May-17-21 07:00AM]
31-03-2021	AH		FBIO	Fortress Biotech, Inc.	319.00	-0.06	-0.18	0.00	Fortress Biotech EPS beats by $0.34, beats on revenue [3/31/2021 4:53 PM]	3.86	0.33 (9.33%)	3.70	0.17 (4.82%)	1.74 - 5.08	899,002	830,000	48,485
Fortress Biotech EPS beats by $0.34, beats on revenue [3/31/2021 4:53 PM] Eli Lilly subsidiary to divest Qbrexza to Journey Medical [4/1/2021 3:40 PM] Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights [Mar-31-21 04:15PM] NASDAQ: FBIO Investor Notice: Lawsuit against Fortress Biotech, Inc. announced by Shareholders Foundation [Mar-30-21 07:25AM] Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA® [Apr-01-21 07:00AM] Fortress Biotech's Partner Firm Expands Footprint In Dermatology With Qbrexza Acquisition [Apr-01-21 09:02AM]
09-11-2020	AH		FBIO	Fortress Biotech, Inc.	213.86	-0.20	-0.28	-0.44	Fortress Biotech EPS misses by $0.02, misses on revenue [11/9/2020 4:30 PM]	2.34	0.0 (-0.21%)	2.45	0.11 (4.70%)	1.04 - 4.78	630,422	941,722	1,061